Pharma Equity Group A/S – Challenge to Arbitral Award
| 07 September 2026
Announcement no. 11
Pharma Equity Group A/S – Challenge to Arbitral Award
Pharma Equity Group A/S (“PEG”) has been notified that Interpatium – Promoção Imobiliária LDA has commenced proceedings before the District Court of Helsingør seeking to have the arbitral award dated 12 June 2026 set aside.
PEG disputes the grounds for the proceedings and will protect the Company’s interests throughout the legal process.
The commencement of the proceedings does not in itself suspend the enforceability of the arbitral award, and PEG will therefore continue its enforcement efforts pursuant to the award.
Under the arbitral award, Interpatium is required to pay PEG EUR 10.5 million plus interest and costs.
For further information, please contact: | |
| Christian Vinding Thomsen, Chairman of the Board of Directors of Pharma Equity Group A/S, phone: +45 2622 7222 |
About Pharma Equity Group A/S
Pharma Equity Group is a listed company on Nasdaq Copenhagen’s main list. The company’s main focus is on promoting the various drug candidates in its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on Health Care, Pharma Equity Group’s primary goal is to add significant value to Reponex Pharmaceuticals’ various drug candidates.
The Company is committed to providing comprehensive support, resources, and expertise to drive the development and success of these drug candidates. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals and prioritizes the promotion of innovative medical solutions and cutting-edge treatments. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while remaining – in the longer term – open to new strategic investments for continued growth.
Attachment
